The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a heterogeneous disorder characterized by defects in insulin secretion and action. Insulin resistance is a key feature of type 2 diabetes. However, insulin resistance alone does not appear to be sufficient to cause diabetes. Longitudinal studies have shown that the development of overt hyperglycemia is associated with a decline in beta-cell secretion. In patients with impaired glucose tolerance or in the early stages of type 2 diabetes, first-phase insulin release is almost invariably lost despite the enhancement of second-phase secretion. Both animal and human studies support the critical physiologic role of the first-phase of insulin secretion in the maintenance of postmeal glucose homeostasis. This effect is primarily mediated at the level of the liver, allowing prompt inhibition of endogenous glucose production (EGP) and thereby restraining the mealtime rise in plasma glucose. In type 2 diabetes, the loss of the early surge of insulin release is a precocious and quite common defect that plays a pathogenic role in postmeal hyperglycemia and one that may require specific therapeutic intervention. This becomes even more apparent if the negative impact of prandial glucose spikes is taken into consideration. Epidemiological evidence exists to indicate that 2-h postload plasma glucose levels are strongly associated with all-cause and cardiovascular mortality relative risk. Indeed the acute elevation of plasma glucose concentration triggers an array of tissue responses that may contribute to the development of diabetic complications. Considering that type 2 diabetes begins with meal-related hyperglycemia in many patients, it becomes apparent that normalization of postmeal plasma glucose levels should be the target for rational therapy and the goal in the early stages of the disease. If a primary goal of diabetes therapy is control of postmeal glucose excursion, then the regulation of glucose absorption from the gut and entry into the circulation is an important mechanism to consider. The restoration of the rapid increase in plasma insulin concentration may be quite an efficient therapeutic approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441 · cited 1×
“production of free radicals [49] with ensuing oxidative”
BackgroundWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“Moreover, since acute insulin release plays a major role in ensuring normal glucose tolerance, and its impairment occurs early in the natural history of type 2 diabetes [13], not only does restoration of first-phase insulin secretion appear to be a rational therapeutic approach but it may also prove of value in preven…”
Background(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873 · cited 1×
“[57], carried out in newly diagnosed patients with type 2”
BackgroundEarly Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes Mellitus
Eriksson, J., Franssila-Kallunki, A., Ekstrand, A., Saloranta, C., Widén, E., Schalin, C., & Groop, L. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908103210601 · Cited by 807
Mitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 7×
“IGT [16], Gerich and colleagues found an inverse”
BackgroundInfluential
Cited by
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes
Del Guerra, S., Lupi, R., Marselli, L., Masini, M., Bugliani, M., Sbrana, S., Torri, S., Pollera, M., Boggi, U., Mosca, F., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.3.727 · Cited by 466
Self-citationAcquisition of Dynamic Function in Human Stem Cell-Derived β Cells
Velazco-Cruz, L., Song, J., Maxwell, K. G., Goedegebuure, M. M., Augsornworawat, P., Hogrebe, N. J., & Millman, J. R. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.12.012 · Cited by 399
Fehse, F., Trautmann, M., Holst, J. J., Halseth, A. E., Nanayakkara, N., Nielsen, L. L., Fineman, M. S., Kim, D. D., & Nauck, M. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1093 · Cited by 297
“(32) and calculated from C-peptide concentrations using the insulin SECretion (ISEC) computer program (3, 33).”
BackgroundMethodβ-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
Saisho, Y. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i1.109 · Cited by 263
Maxwell, K. G., Augsornworawat, P., Velazco-Cruz, L., Kim, M. H., Asada, R., Hogrebe, N. J., Morikawa, S., Urano, F., & Millman, J. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax9106 · Cited by 183
Andersson, S. A., Olsson, A. H., Esguerra, J. L. S., Heimann, E., Ladenvall, C., Edlund, A., Salehi, A., Taneera, J., Degerman, E., Groop, L., et al. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.009 · Cited by 122
Gower, B. A., Granger, W. M., Franklin, F., Shewchuk, R. M., & Goran, M. I. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8498 · Cited by 114
“Impaired, rather than excessive, first phase insulin secretion is associated with subsequent development of glucose intolerance and type 2 diabetes (26).”
BackgroundDalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Low carbohydrate dietary approaches for people with type 2 diabetes-a narrative review
Wheatley, S. D., Deakin, T. A., Arjomandkhah, N. C., Hollinrake, P. B., & Reeves, T. E. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.687658 · Cited by 50
First-phase insulin secretion: can its evaluation direct therapeutic approaches?
Di Giuseppe, G., Ciccarelli, G., Soldovieri, L., Capece, U., Cefalo, C. M. A., Moffa, S., Nista, E. C., Brunetti, M., Cinti, F., Gasbarrini, A., et al. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.02.001 · Cited by 46
PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control
Kaihara, K. A., Dickson, L. M., Ellenbroek, J. H., Orr, C. M. D., Layden, B. T., & Wicksteed, B. (2015) · Diabetes · doi:10.2337/db14-1051 · Cited by 22
“The association of impaired AIR with the early stages of T2DM and its importance in determining the rate of glucose clearance make its improvement an attractive target for therapies to restore b-cell function (38,39).”
Metadata
- Authors
- Del Prato, S., & Tiengo, A.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2001
- Volume
- 17
- Issue
- 3
- Pages
- 164-174
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2011571924
- Cited by
- 238
- References
- 23
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.